Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: March 21, 2005
Last updated: January 29, 2015
Last verified: January 2015